A study combining genetic data and statistical modeling has generated some of the first epidemiologic estimates for neurodevelopment disorders caused by de novo variants. It promises much-needed guidance on priorities around these rare diseases.
Researchers have developed the first polygenic risk score that distinguishes on a cohort level between patients with epilepsy and controls, as well as between patients with generalized and focal epilepsies.
Should everyone with dilated cardiomyopathy undergo a genetic profile? This discussion with a heart failure and genetics expert offers guidance until results of the DCM Precision Medicine Study come in.
No large-scale Parkinson’s disease genetic studies have ever been conducted in Latino populations — until now. The leader of the LARGE-PD cohort study explains its rationale and goals.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The grant will fund exploration of whether the genetic composition of lung cancer cells can predict response to and perhaps guide strategy for radiotherapy.
Familial studies have linked three areas of the genome to mitral valve prolapse risk. A new population-based study of 500 patients is casting the net more broadly. Results are due in 2018.
Biologic Therapies VII Summit in April 2-17 will help clinicians understand and harness the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.
Charis Eng, MD, PhD, Chair and Director of Cleveland Clinic’s Genomic Medicine Institute, shares her views on genetics-related Top 10 Innovations.
Recording patients’ family medical history and including it in their medical record is important in prevention, risk reduction and early detection of disease.
As key members of the Center for Personalized Genetic Healthcare, genetic counselors translate complicated data into information patients can readily understand.